Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2006

Reckamp Karen L, Krysan Kostyantyn, Morrow Jason D, Milne Ginger L, Newman Robert A, Tucker Christopher, Elashoff Robert M, Dubinett Steven M, Figlin Robert A

Abstract excerpt

PURPOSE: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI)-resistant manner. Because preclinical data indicated that tumor COX-2 expression caused resistance to EGFR TKI, a phase I trial to establish the optimal biological dose (OBD), defined as the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Quinazolines
Share to Cyclooxygenase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Therapy, Combination

Share to Erlotinib Hydrochloride

Share to Maximum Tolerated Dose

Share to Pyrazoles

Share to Sulfonamides

Source

Identifiers

PMID: 16740761
DOI: 10.1158/1078-0432.CCR-06-0112

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.PMID 16740761Read ↗

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.Semantic proximity Read ↗

Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.Semantic proximity Read ↗

The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.Semantic proximity Read ↗

Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer.Semantic proximity Read ↗

Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.Semantic proximity Read ↗

Cytotoxic effects of dimethyl-celecoxib (DMC) on bone tumor cell line MG63 and cell line HEK293Semantic proximity Read ↗

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Semantic proximity Read ↗

Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.Semantic proximity Read ↗

Antimutagenic and anti-oxidant activities of the non-steroidal anti-inflammatory drug celecoxib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.